Beijing has broken ground on what developers call China's first production line for AI-assisted personalised tumour vaccines. The facility, set to be completed by October, aims to address the needs of millions of new cancer patients annually in a nation where the disease is the second-leading cause of death.
The project is being led by Likang Life Sciences, based in Beijing. The new drug research and manufacturing centre is located in the Beijing Economic and Technological Development Zone, representing a significant step in applying artificial intelligence to oncology treatment.
Total investment in the centre is approximately 110 million yuan (US$16.1 million), according to the developer. The AI-powered approach is intended to customise vaccines to individual patients' tumour profiles, potentially increasing treatment efficacy.
This development could accelerate the availability of personalised cancer therapies in China, though broad clinical impact will depend on regulatory approvals and production scalability. The project highlights Beijing's push to integrate AI into biotech manufacturing.
No independent verification of timelines or efficacy claims was available from other sources. Critics may question whether AI-driven personalisation can deliver meaningful improvements over existing vaccine technologies at scale.